Fractional Flow Reserve-Guided Renal Artery Stenting in Renovascular Hypertension: 1-Year Results of the FAIR Study.
Y, L., R, Z., X, L., J, Z., C, L., F, F., F, Z., J, Q., Z, L., & S, Z. (2026). Fractional Flow Reserve-Guided Renal Artery Stenting in Renovascular Hypertension: 1-Year Results of the FAIR Study.. JACC. Cardiovascular interventions. https://doi.org/10.1016/j.jcin.2026.05.019
Y L, R Z, X L, J Z, C L, F F, et al. Fractional Flow Reserve-Guided Renal Artery Stenting in Renovascular Hypertension: 1-Year Results of the FAIR Study.. JACC. Cardiovascular interventions. 2026; doi: 10.1016/j.jcin.2026.05.019
Y L, R Z, X L, et al. Fractional Flow Reserve-Guided Renal Artery Stenting in Renovascular Hypertension: 1-Year Results of the FAIR Study.[J]. JACC. Cardiovascular interventions. 2026. DOI: 10.1016/j.jcin.2026.05.019.
@article{y2026,
author = {Li Y and Zheng R and Liu X and Zheng J and Lu C and Fan F and Zhou F and Qiu J and Lin Z and Zhou S},
title = {Fractional Flow Reserve-Guided Renal Artery Stenting in Renovascular Hypertension: 1-Year Results of the FAIR Study.},
journal = {JACC. Cardiovascular interventions},
year = {2026},
doi = {10.1016/j.jcin.2026.05.019},
note = {PMID: 42442896},
}
TY - JOUR AU - Li Y AU - Zheng R AU - Liu X AU - Zheng J AU - Lu C AU - Fan F AU - Zhou F AU - Qiu J AU - Lin Z AU - Zhou S TI - Fractional Flow Reserve-Guided Renal Artery Stenting in Renovascular Hypertension: 1-Year Results of the FAIR Study. T2 - JACC. Cardiovascular interventions PY - 2026 DO - 10.1016/j.jcin.2026.05.019 AN - PMID:42442896 ER -
BACKGROUND: Whether fractional flow reserve (FFR)-guided revascularization improves outcomes in atherosclerotic renal artery stenosis (ARAS) remains uncertain. OBJECTIVES: This study will evaluate whether the benefit of FFR-guided stenting sustained at 1 year including renal outcomes. METHODS: FAIR pilot is an investigator-initiated, multicentre, open-label trial with blinded endpoint adjudication. Adults with ARAS were randomized 1:1 to FFR-guided vs angiography-guided groups. Stenting was performed in the FFR-guided group when FFR <0.80, and it was performed for all in the angiography-guided group regardless of FFR. The percentage changes in ambulatory daytime mean systolic blood pressure (DMSBP), composite index of antihypertensive medicines (CIAHM), and renal outcomes were analyzed for 1 year. RESULTS: Among all 107 randomized patients, 1-year follow-up was achieved in 50 (93%) in the FFR-guided group and 51 (96%) in the angiography-guided group. At 1 year, DMSBP, CIAHM, and renal outcomes were similar between the groups, while stenting rate was lower with FFR guidance (46% vs 100%, P < 0.01). Patients with FFR <0.80 who underwent stenting experienced the greatest blood pressure reductions (median [IQR] ΔDMSBP: 13 [4, 21] mm Hg at 3 months; 8 [3, 16] mm Hg at 6 months, 7 [0, 16] mm Hg at 12 months; all paired P < 0.05) and sustained declines in CIAHM (2 [0, 5] at 3, 6, and 12 months; all paired P < 0.05). Significant 12-month estimated glomerular filtration rate improvement after stenting was only observed when FFR <0.80, with greater percentage eGFR improvement under quantile regression analysis. CONCLUSIONS: At the 1-year follow-up, FFR-guided renal artery stenting reduced stent use without loss of blood pressure control or renal safety compared with angiography guidance.